Medtronic PLC $MDT Stock Sold by Armstrong Henry H Associates Inc.

Posted by Stanley Muller on Oct 7th, 2026

Armstrong Henry H Associates Inc. cut its stake in Medtronic PLC (NYSE:MDT – Free Report) by 8.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 86,445 shares of the medical technology company’s stock after selling 7,835 shares during the quarter. Medtronic makes up 0.7% of Armstrong Henry H Associates Inc.’s portfolio, making the stock its 13th biggest holding. Armstrong Henry H Associates Inc.’s holdings in Medtronic were worth $7,459,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in MDT. BlackRock Inc. increased its holdings in shares of Medtronic by 0.7% during the 2nd quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company’s stock valued at $8,919,846,000 after acquiring an additional 838,220 shares during the last quarter. State Street Corp increased its position in shares of Medtronic by 2.7% during the second quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock valued at $5,005,320,000 after purchasing an additional 1,658,301 shares during the period. Bank of America Corp DE boosted its position in shares of Medtronic by 5.4% during the 1st quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company’s stock valued at $2,254,200,000 after acquiring an additional 1,343,220 shares in the last quarter. First Eagle Investment Management LLC grew its stake in shares of Medtronic by 37.2% in the 2nd quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock valued at $1,078,321,000 after purchasing an additional 3,739,288 shares during the period. Finally, WCM Investment Management LLC acquired a new stake in shares of Medtronic in the 1st quarter valued at $965,922,000. 82.06% of the stock is owned by institutional investors.

Insider Activity at Medtronic

In related news, EVP Harry Kiil sold 1,483 shares of the business’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total value of $138,882.95. Following the transaction, the executive vice president owned 42,186 shares in the company, valued at $3,950,718.90. The trade was a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.27% of the company’s stock.

Medtronic Stock Performance

NYSE:MDT traded down $0.50 during mid-day trading on Wednesday, reaching $86.59. 19,783,249 shares of the company’s stock were exchanged, compared to its average volume of 9,878,357. The firm has a market capitalization of $110.76 billion, a PE ratio of 21.35, a price-to-earnings-growth ratio of 2.00 and a beta of 0.55. Medtronic PLC has a one year low of $73.31 and a one year high of $106.33. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07. The business’s fifty day simple moving average is $90.22 and its two-hundred day simple moving average is $84.76.

Medtronic (NYSE:MDT – Get Free Report) last announced its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The firm had revenue of $9.76 billion for the quarter, compared to the consensus estimate of $9.55 billion. During the same period in the prior year, the company posted $1.26 earnings per share. The business’s revenue for the quarter was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Analysts anticipate that Medtronic PLC will post 5.98 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be issued a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 annualized dividend and a yield of 3.3%. Medtronic’s payout ratio is presently 70.94%.

Wall Street Analyst Weigh In

A number of research firms have commented on MDT. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $92.00 price objective on shares of Medtronic in a research note on Thursday, September 3rd. TD Cowen reissued a “buy” rating and issued a $110.00 target price on shares of Medtronic in a research note on Wednesday, September 30th. UBS Group increased their price target on Medtronic from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, September 3rd. Robert W. Baird increased their target price on Medtronic from $91.00 to $100.00 and gave the stock a “neutral” rating in a report on Wednesday, September 2nd. Finally, Barclays initiated coverage on shares of Medtronic in a report on Tuesday. They issued an “equal weight” rating and a $95.00 price objective on the stock. Eighteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $102.92.

Check Out Our Latest Report on MDT

Medtronic Company Profile

(Free Report)

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.